Standards of care for type 2 diabetes in China

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 5, 2016, Pages 442-458

  Weng, Jianping ^a   Ji, Linong ^b   Jia, Weiping ^c   Lu, Juming ^d   Zhou, Zhiguang ^e   Zou, Dajin ^f   Zhu, Dalong ^g   Chen, Liming ^h   Chen, Li ⁱ   Guo, Lixin ^j   Guo, Xiaohui ^k   Ji, Qiuhe ^l   Li, Qifu ^m   Li, Xiaoying ⁿ   Liu, Jing ^o   Ran, Xingwu ^p   Shan, Zhongyan ^q   Shi, Lixin ^r   Song, Guangyao ^s   Yang, Liyong ^t   Yang, Yuzhi ^u   Yang, Wenying ^v   more..

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^h TIANJIN MEDICAL UNIVERSITY   (China)

ⁱ SHANDONG UNIVERSITY   (China)

^j BEIJING HOSPITAL   (China)

^k PEKING UNIVERSITY FIRST HOSPITAL   (China)

^l FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^m THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

ⁿ SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^o GANSU PROVINCIAL HOSPITAL   (China)

^p SICHUAN UNIVERSITY   (China)

^q CHINA MEDICAL UNIVERSITY   (China)

^r GUIZHOU MEDICAL UNIVERSITY   (China)

^s HEBEI GENERAL HOSPITAL   (China)

^t FUJIAN MEDICAL UNIVERSITY   (China)

^u HEILONGJIANG PROVINCIAL HOSPITAL   (China)

^v CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; MITIGLINIDE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ANTIDIABETIC ACTIVITY; ARTICLE; BARIATRIC SURGERY; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHINA; CLASSIFICATION; DIABETES EDUCATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET THERAPY; EPIDEMIC; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LOWER EXTREMITY VASCULAR DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PATIENT CARE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REHABILITATION; RURAL AREA; SECONDARY PREVENTION; URBAN AREA; VASCULAR DISEASE;

EID: 84979527286     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2827     Document Type: Article

References (97)

1. National Diabetes Study Group. A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China. Zhonghua Nei Ke Za Zhi 1981; 20(11): 678–683.
2. Pan XR, Yang WY, Li GW, et al., Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997; 20(11): 1664–1669.
3. Li LM, Rao KQ, Kong LZ, et al. A description on the Chinese national nutrition and health survey in 2002. Zhonghua Liu Xing Bing Xue Za Zhi 2005; 26(7): 478–484.
4. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362(12): 1090–1101.
5. Chinese Diabetes Society. China guideline for type 2 diabetes (2010). Chin J Diabetes 2012; 20(1): S1–S36.
6. Jia WP, Pang C, Chen L, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia 2007; 50(2): 286–292.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539–553.
8. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1): S62–S69.
9. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. 2011.
10. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708–723.
11. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403.
12. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343–1350.
13. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(9323): 2072–2077.
14. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371(9626): 1783–1789.
15. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368(9548): 1673–1679.
16. Knowler WC, Fowler SE, Hamman RF, et al. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374(9702): 1677–1686.
17. Lian F, Li G, Chen X, et al. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 2014; 99(2): 648–655.
18. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155–161.
19. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368(9541): 1096–1105.
20. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364(12): 1104–1115.
21. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376(9735): 103–111.
22. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–986.
23. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44(11): 1249–1258.
24. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21–B29.
25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865.
26. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589.
27. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643–2653.
28. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703–713.
29. Snow V, Weiss KB, Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138(7): 587–592.
30. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005–2016.
31. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685–696.
32. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574.
33. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300(18): 2134–2141.
34. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849–1860.
35. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010; 87(2): 211–218.
36. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560–2572.
37. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129–139.
38. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53(3): 298–304.
39. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010; 33(6): 1395–1402.
40. Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28(5): 1151–1157.
41. Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29(6): 1220–1226.
42. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304(1): 61–68.
43. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–2572.
44. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23(6): 579–593.
45. American Diabetes Association. Standards of medical care in diabetes – 2010. Diabetes Care 2010; 33(Suppl 1): S11–S61.
46. CG NIFH. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 66[DB/OL]. (2008-05-12)[2013-11-12].
47. Boule NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001; 286(10): 1218–1227.
48. Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006; 29(11): 2518–2527.
49. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20(4): 537–544.
50. Shimizu T, Nathan DM, Buse JB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Nihon Rinsho 2012; 70(Suppl 3): 591–601.
51. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 3: D2966.
52. Ji L, Li H, Guo X, et al. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS One 2013; 8(2): e57222.
53. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 4: D2967.
54. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15(6): 737–754.
55. Sherifali D, Nerenberg K, Pullenayegum E, et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010; 33(8): 1859–1864.
56. Ji L, Tong X, Wang H, et al. Efficacy and safety of traditional Chinese medicine for diabetes: a double-blind, randomised, controlled trial. PLoS One 2013; 8(2): e56703.
57. Hernandez AV, Usmani A, Rajamanickam A, et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 2011; 11(2): 115–128.
58. Cai X, Luo Y, Han X, et al. Meta-analysis of efficacy and safety of nateglinide in Asian type 2 diabetes. Chin J Diabetes 2013; 21(10): 913–917.
59. Wang W, Bu R, Su Q, et al. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. Expert Opin Pharmacother 2011; 12(18): 2791–2799.
60. Cai X, Han X, Luo Y, et al. Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian. PLoS One 2013; 8(11): e79421.
61. Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2014; 2(1): 46–55.
62. Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India and Korea. Diabetes Res Clin Pract 2009; 83: 106–116.
63. Dhillon S, Weber J. Saxagliptin. Drugs 2009; 69: 2103–2114.
64. Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25(4): 435–441.
65. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab 2011; 13(1): 81–88.
66. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092–1100.
67. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83(1): 69–76.
68. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371(9626): 1753–1760.
69. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27(11): 2597–2602.
70. Zhu F, Ji L, Han X, et al. Induction of long-term good glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Chin J Diabetes 2003; 11(1): 5–9.
71. Weng J, Li Y, Xu W, et al. The effects of short-term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients. Chin J Diabetes 2003; 11(1): 10–15.
72. Lu B, Song X, Dong X, et al. High prevalence of chronic kidney disease in population-based patients diagnosed with type 2 diabetes in downtown Shanghai. J Diabetes Complications 2008; 22(2): 96–103.
73. Kramer H, Molitch ME. Screening for kidney disease in adults with diabetes. Diabetes Care 2005; 28(7): 1813–1816.
74. Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010; 21(4): 556–563.
75. Lu B, Gong W, Yang Z, et al. An evaluation of the diabetic kidney disease definition in Chinese patients diagnosed with type 2 diabetes mellitus. J Int Med Res 2009; 37(5): 1493–1500.
76. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17(10): 2937–2944.
77. Dong X, He M, Song X, et al. Performance and comparison of the Cockcroft–Gault and simplified modification of diet in renal disease formulae in estimating glomerular filtration rate in a Chinese type 2 diabetic population. Diabet Med 2007; 24(12): 1482–1486.
78. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 1004–1010.
79. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–860.
80. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–878.
81. Chew EY, Ambrosius WT. Update of the ACCORD eye study. N Engl J Med 2011; 364(2): 188–189.
82. Standards of medical care in diabetes – 2012. Diabetes Care 2012; 35(Suppl 1): S11–S63.
83. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600): 1687–1697.
84. Wilkinson CP, Ferris FR, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110(9): 1677–1682.
85. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008; 9(6): 660–674.
86. Jia WP, Shen Q, Bao YQ, et al. Evaluation of the four simple methods in the diagnosis of diabetic peripheral neuropathy. Zhonghua Yi Xue Za Zhi 2006; 86(38): 2707–2710.
87. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28(4): 956–962.
88. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008; 22(5): 417–442.
89. Lange S, Diehm C, Darius H, et al. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes 2004; 112(10): 566–573.
90. Guan H, Li YJ, Xu ZR, et al. Prevalence and risk factors of peripheral arterial disease in diabetic patients over 50 years old in China. Chin Med Sci J 2007; 22(2): 83–88.
91. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30(1): 162–172.
92. Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44(Suppl 2): S14–S21.
93. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47(3): 385–394.
94. Lawes CM, Parag V, Bennett DA, et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004; 27(12): 2836–2842.
95. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11(3): 309–317.
96. Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013; 126(10): 911–925.
97. Chinese Diabetes Society: Metabolic Syndrome Cooperative Study Group. The suggestion about metabolic syndrome from Chinese diabetes society. Chin J Diabetes Mellitus 2004; 12(3): 156–161.